Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure
| Autor: | Kathryn R Tringale, Anne S Reiner, Ryka R Sehgal, Katherine Panageas, Allison S Betof Warner, Michael A Postow, Nelson S Moss |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | CNS Oncology, Vol 12, Iss 1 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2022-0014 2045-0915 2045-0907 |
| DOI: | 10.2217/cns-2022-0014 |
| Popis: | Aim: Immune checkpoint inhibitor (ICI) efficacy is undefined for melanoma brain metastases (MBM) with concurrent corticosteroid exposure. Materials & methods: We retrospectively evaluated patients with untreated MBM who received corticosteroids (≥1.5 mg dexamethasone equivalent) within 30 days of ICI. mRECIST criteria and Kaplan–Meier methods defined intracranial progression-free survival (iPFS). The lesion size-response association was evaluated with repeated measures modeling. Results: A total of 109 MBM were evaluated. The patient level intracranial response rate was 41%. Median iPFS was 2.3 months and overall survival was 13.4 months. Larger lesions were more likely to progress, with diameter >2.05 cm most predictive of progression (OR: 18.9; 95% CI: 2.6–139.5; p = 0.004). There was no difference in iPFS with steroid exposure pre- versus post-ICI initiation. Conclusion: In the largest reported ICI+corticosteroid cohort, we identify size dependent MBM response. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|